| Literature DB >> 33707599 |
Yin-Chen Hsu1, Chih-Hsiang Yu1, Yan-Ming Chen1, Kathryn G Roberts2, Yu-Ling Ni3, Kai-Hsin Lin4, Shiann-Tarng Jou4,5, Meng-Yao Lu4,5, Shu-Huey Chen6, Kang-Hsi Wu7, Hsiu-Hao Chang4,5, Dong-Tsamn Lin3,4, Shu-Wha Lin1,3, Ze-Shiang Lin1, Wei-Tzu Chiu1, Chia-Ching Chang1, Bing-Ching Ho8, Charles G Mullighan9, Sung-Liang Yu10,11,12,13,14, Yung-Li Yang15,16,17.
Abstract
Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukaemia (ALL), a high-risk subtype characterised by genomic alterations that activate cytokine receptor and kinase signalling, is associated with inferior outcomes in most childhood ALL clinical trials. Half of the patients with Ph-like ALL have kinase rearrangements or fusions. We examined the frequency and spectrum of these fusions using a retrospective cohort of 212 newly diagnosed patients with childhood B-cell ALL. Samples without known chromosomal alterations were subject to multiplex reverse transcription polymerase chain reaction to identify known Ph-like kinase fusions. Immunoglobulin heavy chain locus (IGH) capture and kinase capture were applied to samples without known kinase fusions. We detected known kinase fusions in five of 212 patients, comprising EBF1-PDGFRB, ETV6-ABL1, ZC3HAV1-ABL2, EPOR-IGH, and CNTRL-ABL1. Two patients with P2RY8-CRLF2 were identified. Patients with non-Ph kinase fusions had inferior 5-year event-free survival and overall survival compared with patients with other common genetic alterations. The prevalence of non-Ph kinase fusions in our Taiwanese cohort was lower than that reported in Caucasian populations. Future clinical trials with tyrosine kinase inhibitors may be indicated in Taiwan because of the inferior outcomes for B-cell ALL with kinase fusions.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33707599 PMCID: PMC7952704 DOI: 10.1038/s41598-021-85213-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379